MX2010007605A - Pirrolo-pirimidas y pirrolo-piridinas. - Google Patents

Pirrolo-pirimidas y pirrolo-piridinas.

Info

Publication number
MX2010007605A
MX2010007605A MX2010007605A MX2010007605A MX2010007605A MX 2010007605 A MX2010007605 A MX 2010007605A MX 2010007605 A MX2010007605 A MX 2010007605A MX 2010007605 A MX2010007605 A MX 2010007605A MX 2010007605 A MX2010007605 A MX 2010007605A
Authority
MX
Mexico
Prior art keywords
compounds
pyrrolopyridines
pyrrolopyrimidines
alk
meanings
Prior art date
Application number
MX2010007605A
Other languages
English (en)
Inventor
Catherine Leblanc
Robert Alexander Pulz
Nikolaus Johannes Stiefl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010007605A publication Critical patent/MX2010007605A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Los compuestos de la fórmula I, en forma libre o de sal o de solvato, en donde X. T1, T3 y T4 tienen los significados indicados en la memoria descriptiva, son útiles para el tratamiento de las enfermedades mediadas por el receptor de ALK-5 y/o ALK-4. También se describen composiciones farmacéuticas que contienen los compuestos, y procesos para la preparación de los compuestos. (ver fórmula (I)).
MX2010007605A 2008-01-11 2009-01-09 Pirrolo-pirimidas y pirrolo-piridinas. MX2010007605A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08150182 2008-01-11
PCT/EP2009/050225 WO2009087225A2 (en) 2008-01-11 2009-01-09 Pyrrolopyrimidines and pyrrolopyridines

Publications (1)

Publication Number Publication Date
MX2010007605A true MX2010007605A (es) 2010-08-02

Family

ID=39445770

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007605A MX2010007605A (es) 2008-01-11 2009-01-09 Pirrolo-pirimidas y pirrolo-piridinas.

Country Status (22)

Country Link
US (1) US8314112B2 (es)
EP (1) EP2242756A2 (es)
JP (1) JP5643110B2 (es)
KR (1) KR20100116606A (es)
CN (1) CN101970435B (es)
AR (1) AR070127A1 (es)
AU (1) AU2009203694B2 (es)
BR (1) BRPI0907231A2 (es)
CA (1) CA2711845A1 (es)
CL (1) CL2009000028A1 (es)
CO (1) CO6331340A2 (es)
CR (1) CR11554A (es)
EA (1) EA201001126A1 (es)
EC (1) ECSP10010335A (es)
IL (1) IL206819A0 (es)
MA (1) MA31952B1 (es)
MX (1) MX2010007605A (es)
PE (1) PE20091306A1 (es)
TN (1) TN2010000305A1 (es)
TW (1) TW200934781A (es)
WO (1) WO2009087225A2 (es)
ZA (1) ZA201004602B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5211063B2 (ja) * 2006-11-30 2013-06-12 ジェネンテック， インコーポレイテッド アザ−インドリル化合物及び使用方法
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
WO2009126584A1 (en) 2008-04-07 2009-10-15 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
LT2300013T (lt) 2008-05-21 2017-12-27 Ariad Pharmaceuticals, Inc. Fosforo dariniai kaip kinazių inhibitoriai
CA2676946A1 (en) 2009-08-28 2011-02-28 Lucie Peduto Adam12 inhibitors and their use against inflammation-induced fibrosis
EP2475666A2 (en) 2009-09-11 2012-07-18 Trius Therapeutics, Inc. Gyrase inhibitors
ES2667049T3 (es) 2010-02-05 2018-05-09 Merck Patent Gmbh Derivados de heteroaril-[1,8]naftiridina
ES2528441T3 (es) 2010-02-22 2015-02-10 Merck Patent Gmbh Hetarilaminonaftiridinas
WO2011104183A1 (en) * 2010-02-24 2011-09-01 Syngenta Participations Ag Novel microbicides
MX2012015023A (es) 2010-06-30 2013-04-03 Fujifilm Corp Derivado novedoso de nicotinamida o sal del mismo.
PL2624696T3 (pl) 2010-10-06 2017-07-31 Glaxosmithkline Llc Pochodne benzimidazolu jako inhibitory kinazy PI3
MY161199A (en) 2011-03-23 2017-04-14 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
WO2012151561A1 (en) 2011-05-04 2012-11-08 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
ES2676180T3 (es) 2011-07-01 2018-07-17 Novartis Ag Terapia de combinación que comprende un inhibidor de CDK4/6 y un inhibidor de PI3K para el uso en el tratamiento de cáncer
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
RU2014151004A (ru) 2012-06-07 2016-08-10 Ф. Хоффманн-Ля Рош Аг Пирролопиримидоновые и пирролопиридоновые ингибиторы танкиразы
SG11201408816QA (en) * 2012-07-03 2015-03-30 Aurigene Discovery Tech Ltd 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
WO2014160203A2 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9776997B2 (en) 2013-06-04 2017-10-03 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-A]pyridines and their use
CN106459090A (zh) 2014-02-19 2017-02-22 拜耳制药股份公司 3‑(嘧啶‑2‑基)咪唑并[1,2‑a]吡啶
WO2015148654A1 (en) * 2014-03-26 2015-10-01 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
WO2016011019A1 (en) 2014-07-15 2016-01-21 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
MX2017003930A (es) 2014-09-26 2017-06-30 Gilead Sciences Inc Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank.
JP2017536396A (ja) 2014-12-02 2017-12-07 バイエル・ファルマ・アクティエンゲゼルシャフト ヘテロアリール置換イミダゾ［１，２−ａ］ピリジンおよびその使用
WO2016172496A1 (en) 2015-04-23 2016-10-27 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
WO2016183071A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
FR3041640B1 (fr) 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
KR20180094976A (ko) 2015-12-17 2018-08-24 길리애드 사이언시즈, 인코포레이티드 Tank-결합 키나제 억제제 화합물
CA3008171A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
KR20230111268A (ko) 2016-03-28 2023-07-25 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
AU2017250302B2 (en) 2016-04-15 2021-01-21 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
FI3532459T3 (fi) 2016-10-26 2023-10-23 Constellation Pharmaceuticals Inc Lsd1-estäjiä ja niiden lääkinnällisiä käyttöjä
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
EP3988552A1 (en) 2017-09-27 2022-04-27 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
US11236086B2 (en) 2017-10-18 2022-02-01 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
MX2020006613A (es) * 2017-12-22 2020-11-13 Ravenna Pharmaceuticals Inc Derivados de aril-bipiridina amina como inhibidores de fosfatidilinositol fosfato cinasa.
JP2021517574A (ja) * 2018-03-23 2021-07-26 サイトーＣｙｔｏｏ 骨格筋肥大誘発剤としてのａｌｋ５阻害剤
AR117600A1 (es) 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
US20200247812A1 (en) * 2018-07-10 2020-08-06 Integral Biosciences Private Limited Heterocyclic compounds and methods of use
CN111018858B (zh) * 2018-10-10 2022-11-18 复旦大学 杂环类衍生物及其制备方法和用途
TWI827760B (zh) * 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
KR20200105246A (ko) * 2019-02-28 2020-09-07 한미약품 주식회사 아데노신 수용체 길항제로서 신규 화합물 및 이를 포함하는 약학 조성물
US20230145793A1 (en) * 2020-03-16 2023-05-11 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Substituted pyrimidine or pyridine amine derivative, composition thereof, and medical use thereof
CN113698395B (zh) * 2020-05-22 2023-12-08 赛诺哈勃药业（成都）有限公司 转化生长因子受体拮抗剂、其制备方法和应用
JP2023529867A (ja) 2020-06-05 2023-07-12 キネート バイオファーマ インク． 線維芽細胞増殖因子受容体キナーゼの阻害剤
KR20230051500A (ko) 2020-07-15 2023-04-18 키에시 파르마슈티시 엣스. 피. 에이. Alk5 억제제로서 피리다진일 아미노 유도체
AU2021307560A1 (en) 2020-07-15 2023-02-23 Chiesi Farmaceutici S.P.A. Pyrido oxazine amino derivatives as ALK5 inhibitors
US20240116947A1 (en) 2020-07-15 2024-04-11 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
US20240116948A1 (en) 2020-12-23 2024-04-11 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
WO2023046698A1 (en) 2021-09-21 2023-03-30 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
WO2023208986A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Imidazole derivatives as alk5 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL175347B1 (pl) 1992-04-03 1998-12-31 Upjohn Co Trójpierścieniowe heterocykliczne aminy aktywne farmaceutycznie
US6686366B1 (en) * 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
CA2365401A1 (en) * 1999-03-11 2000-10-05 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands
AU784878B2 (en) 1999-12-02 2006-07-13 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 A2A and A3 receptors and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
BR0115847A (pt) 2000-12-01 2004-02-25 Osi Pharm Inc Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
JP2005529062A (ja) 2001-11-30 2005-09-29 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アデノシンａ１及びａ３受容体に特異的な化合物とその使用
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
ES2305744T3 (es) * 2003-03-12 2008-11-01 Millennium Pharmaceuticals, Inc. Derivados de quinazolina como inhibidores e tgf-beta.
US20050205625A1 (en) * 2004-03-16 2005-09-22 House Arthur G Container support device, system, and method
PL1853270T3 (pl) 2005-02-18 2010-09-30 Solvay Pharm Gmbh Kompozycje farmaceutyczne zawierające inhibitory - NEP, inhibitory układu wytwarzającego endogenną endotelinę i diuretyki
US20060205625A1 (en) 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
US20070014956A1 (en) * 2005-07-14 2007-01-18 Mccarthy Dillon P Adhesive tape device
PL1962830T3 (pl) * 2005-12-23 2013-08-30 Glaxosmithkline Llc Azaindolowe inhibitory kinaz aurora

Also Published As

Publication number Publication date
EA201001126A1 (ru) 2011-02-28
CR11554A (es) 2010-08-11
JP2011509279A (ja) 2011-03-24
CL2009000028A1 (es) 2009-07-17
BRPI0907231A2 (pt) 2019-09-24
CN101970435A (zh) 2011-02-09
AR070127A1 (es) 2010-03-17
WO2009087225A3 (en) 2009-11-05
ZA201004602B (en) 2011-03-30
US20090181941A1 (en) 2009-07-16
TN2010000305A1 (en) 2011-11-11
WO2009087225A2 (en) 2009-07-16
AU2009203694A1 (en) 2009-07-16
ECSP10010335A (es) 2010-08-31
IL206819A0 (en) 2010-12-30
TW200934781A (en) 2009-08-16
JP5643110B2 (ja) 2014-12-17
AU2009203694B2 (en) 2012-04-26
EP2242756A2 (en) 2010-10-27
CN101970435B (zh) 2014-07-02
MA31952B1 (fr) 2010-12-01
KR20100116606A (ko) 2010-11-01
US8314112B2 (en) 2012-11-20
CA2711845A1 (en) 2009-07-16
PE20091306A1 (es) 2009-09-24
CO6331340A2 (es) 2011-10-20

Similar Documents

Publication Publication Date Title
TN2010000305A1 (en) Pyrrolopyrimidines and pyrrolopyridines
ZA201000079B (en) Organic compounds
TN2010000167A1 (en) Organic compounds
EA201001687A1 (ru) Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 )
MY150059A (en) Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
MX339899B (es) Compuestos de triazolopiridina como inhibidores de pim cinasa.
MX2009004715A (es) Compuestos heterociclicos como agentes antiinflamatorios.
MX2009010728A (es) Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
IN2012DN02577A (es)
TW200637863A (en) Organic compounds
MX2013010898A (es) Novedoso derivados de la pirimidina.
MX2010009646A (es) Agentes terapeuticos antivirales.
IN2012DN01641A (es)
MX2012013274A (es) Novedosos derivados de la pirimidina.
TW200630366A (en) Organic compounds
IN2012DN01642A (es)
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
WO2007068473A3 (en) Organic compounds
EA201101604A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины в качестве лигандов андрогенового рецептора
NZ594186A (en) Indole derivatives as anticancer agents
TN2013000483A1 (en) Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
CU20100147A7 (es) Pirrolo-pirimidinas y pirrolo-piridinas
UA100390C2 (en) Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors

Legal Events

Date Code Title Description
FG Grant or registration